The branched DNA hybridization assay has been improved by the inclusion of the novel nucleotides, isoC and isoG, in the amplification sequences to prevent non-specific hybridization. The novel isoC, isoG-containing amplification sequences have no detectable interaction with any natural DNA sequence. The control of non-specific hybridization in turn permits increased signal amplification. Addition of a 14 site preamplifier was found to increase the signal/noise ratio 8-fold. A set of 74 oligonucleotide probes was designed to the consensus HIV POL sequence. The detection limit of this new HIV branched DNA amplifier assay was ∼50 molecules/ml. The assay was used to measure viral load in 87 plasma samples of HIV-infected patients on triple drug therapy whose RNA titers were <500 molecules/ml. In all 11 patients viral load eventually declined to below the detection limit with the new assay.
INTRODUCTION
Quantitative hybridization assays based on branched DNA signal amplification are widely used to monitor patients on antiviral therapy for human immunodeficiency virus (HIV), hepatitis C (HCV) and hepatitis B (HBV) and to stratify patients for therapy (1) (2) (3) (4) (5) (6) (7) . They have also been used to predict time to onset of AIDS (8) (9) (10) and to establish the kinetics of HIV production and destruction, which has led to new insights into the mechanisms of pathogenesis (11, 12) . The most important characteristics of these hybridization assays are sensitivity, wide dynamic range, and precise and accurate quantification. The branched DNA hybridization assay pictured in Figure 1 employs linear signal amplification rather than exponential amplification of target.
A family of oligonucleotides called capture extenders (CEs) is used to capture the target to the solid support. The target is labeled by virtue of binding a large number (typically >30) of target-specific oligonucleotides called label extenders (LEs). In the first generation assay the LE probes bind a branched DNA amplifier (bDNA), which in turn binds many alkaline phosphatase probes. In the second and third generation assays, the LE probes bind preamplifiers, which in turn bind many amplifiers. The result is stronger signal amplification and lower detection limits. In all versions of the assay, the linearly amplified signal is directly related to the number of targets present in the original sample. This first generation bDNA assay has been shown to quantify nucleic acid targets accurately and precisely between ∼10 000 and 10 000 000 molecules; assays for HIV, HCV and HBV have been developed (13) (14) (15) (16) (17) . The second generation HIV bDNA assay has a quantitative detection limit of 500 molecules (18) .
The recent introduction of HIV protease inhibitors has driven viral loads to below even the detection limits of the second generation HIV bDNA assay (1, 2) . The first and second generations of the assay were limited by non-specific hybridization (NSH) between the amplification sequences and other nucleic acids. Short regions of hybridization between any member of the amplification system (alkaline phosphatase probe, amplifier or preamplifier) and any non-target nucleic acid sequence will lead to amplification of background. Capture probes (CPs), CEs and sample nucleic acids are all sources of this background hybridization. The purpose of this study was to examine the effect of redesigning the amplification molecules by incorporation of the non-natural bases, isocytidine and isoguanosine, to reduce their hybridization potential to all non-target nucleic acids. If targetspecific signal amplification is accomplished without a concomitant amplification of the background from non-target molecules, then sensitivity should be greatly improved.
MATERIALS AND METHODS

Clinical specimens
Blood was collected in EDTA tubes. Plasma was prepared and stored at -80_C until use and virus was concentrated by centrifugation as described (18) .
Oligonucleotide probe design
A consensus HIV POL sequence was generated from the GenBank database using sequences from six subtypes, A-F, and sectioned into 26 nucleotide (nt) fragments, resulting in an average dissociation temperature (T d ) of 72_C. This created 110 possible oligonucleotide probes. A computer program (S.Bushnell et al., in preparation) was used to calculate degeneracy, equilibrium melting temperature (T m ) and dissociation temperature for each oligonucleotide. An initial probe set was selected based on the following criteria: T m > 63_C, T d > 63_C, and degeneracy less than four sites. The program then calculates the homology between the initial probe set and the amplification sequences. It selects probes with the lowest homology (below a user-defined cutoff) to the amplification sequences to be CEs. Finally, probes with the lowest homology to the CP and the CEs are then selected to be LEs. The resulting probe set consisted of 54 LE and 20 CE probes.
Universal sequence design
Sequences for the preamplifier, amplifier and alkaline phosphatase probe were redesigned to contain ∼30% isobases [5-methyl-2′-deoxyisocytidine (isoC) and 5-methyl-2′-deoxyisoguanosine (isoG)]. The sequences were designed to have no secondary structure longer than a trimer, no interactions with any sequence longer than a trimer except with their complements, and to have a melting temperature in excess of 80_C at 1 nM in 3× SSC. The sequences chosen are listed in Table 1 .
Oligonucleotide target design
To measure the improvement in sensitivity with each layer of amplification in the bDNA assay, oligonucleotide targets were designed to hybridize to the CP on the microtiter well and serve as targets for the amplification system. The sequences are listed in Table 2 .
Preamplifier synthesis
Eight oligonucleotides were enzymatically ligated essentially as described (18) to produce a molecule with 14 repeat sequences and one leader sequence.
Amplifier synthesis
A 15×2 branched DNA was constructed essentially as described (19) . An arm consisting of two copies of the amplifier repeat was ligated onto a comb containing one copy of the amplifier leader sequence.
Alkaline phosphatase probe
An alkaline phosphatase probe was prepared essentially as described (20) . Table 1 . Sequences used in the system 8 bDNA amplification assay, which is pictured in Figure 1 Function (copies) Sequence Complement LE tail (1) d(JTATJCGCJCTGFTATJCCG) Preamplifier leader (1) Preamplifier repeat (14) d(TCFACGJCFCTAJGGAFAAFG) Amplifier leader (1) Amplifier repeat (30) d(AGTFAJCGCFGTAFCAAJTJC) Alkaline phosphatase probe (1) The sequences labeled 'leader' appear once in the indicated construct, while sequences labeled 'repeat' appear the indicated number of times. The tail on the LE is a single sequence. F, isoC; J, isoG. All three oligonucleotides possess the same 23 nt 3′ terminal sequence that allows them to hybridize to the CP on the microtiter wells. Oligonucleotide 1 is detected by direct hybridization with the alkaline phosphatase probe; oligonucleotide 2 is detected by hybridization with the bDNA amplifier, which hybridizes to the alkaline phosphatase probe; oligonucleotide 3 is detected by hybridization with the preamplifier, which hybridizes to the amplifier, which hybridizes to the alkaline phosphatase probe. F, isoC; J, isoG; Q, triethyleneglycol spacer. Nucleic Acids Research, 1997, Vol. 25, No. 15 2981
Capture wells
Polystyrene capture wells were prepared essentially as described (21) .
bDNA diluents
Capture diluent. 127 mM LiCl, 5% lithium lauroyl sulfate, 9 mM EDTA, 50 mM HEPES (pH 7.5), 0.05% hespan (DuPont Pharmaceuticals), 0.05% ProClin 300 (Supelco), 0.2% casein (Research Organics, Hammarsten quality).
Amplifier diluent. Prepared by incubating 50% horse serum with 0.5 mg/ml proteinase K in 5× SSC, 1.3% SDS, 6 mM Tris-HCl at 65_C for 2 h and then adding 6 mM phenylmethylsulfonyl fluoride, 0.05% sodium azide, 0.05% ProClin 300 and 10% dextran sulfate (500 000 MW; Pharmacia).
Alkaline phosphatase diluent. Prepared by adding 17 mM MgCl 2 , 0.85 mM ZnCl 2 , and 0.85% Brij 35 to amplifier diluent without dextran sulfate.
System 8 bDNA assay procedure
System 8 is a detection system employing isoC and isoG in the preamplifier, amplifier and alkaline phosphatase probe. Viral pellets were resuspended in capture diluent and solubilized at 63_C for 2 h prior to overnight incubation at 45_C in capture wells. Three serial incubations were done at 45_C with no cool down between steps: preamplifier (5 fmol/50 µl in amplifier diluent) for 30 min, amplifier (5 fmol/50 µl in amplifier diluent) for 30 min, and ap probe (10 fmol/50 µl in alkaline phosphatase diluent) for 15 min. After each incubation step, the wells were washed twice with wash A (18) . An additional three washes with wash D (18) were done after the alkaline phosphatase step, prior to incubation with substrate (18) in the Chiron luminometer. After 30 min at 37_C the luminescence was measured in relative light units (RLU).
Calculation of detection limit
Let D = detection limit, T = Target level, S T = signal at T, and N = assay noise. Detection limit is defined as the target level at which ∆ = 0. The ∆ function is defined by:
where CV is the coefficient of variation, CV s × S = σ s = standard deviation of S, and CV n × N = σ n = standard deviation of N. Let S d = signal at the detection limit, then
At the detection limit, CV s ∼ CV n ∼ CV assay , the average CV of the entire assay. This is true because assays to measure detection limit use points clustered about the detection limit (i.e., all target levels are close to the detection limit). Thus S d ∼ [N(1 + 2CV assay )]/ (1 -2CV assay ). At any point along the S -N curve versus T, one can estimate D as approximately equal to T(S d -N)/(S T -N). The detection limit is estimated for each target level. An average and standard deviation of the detection limit estimated at three or more target levels are then calculated. Linearity, L, was estimated at two or more target levels, T 1 and T 2 , as
A perfectly linear dose-response curve = 100% linearity.
RESULTS
Control of non-specific hybridization by redesign of the amplification sequences with isoC and isoG
To improve the sensitivity of the bDNA assay, while maintaining the precision and accuracy of quantification and the wide dynamic range, all of the amplification sequences were redesigned. In the new design, termed 'system 8 bDNA', approximately every fourth nucleotide of the preamplifier, amplifier and alkaline phosphatase probe is either isoC or isoG (Table 1) , which attenuates the hybridization of these molecules to natural sequences (22, 23) . IsoC and isoG base pair with each other, but not with any of the four natural bases (24) . Sequences containing isoC-isoG base pairs are ∼2_C more stable per base pair than their C-G congeners (24) .
To test the ability of amplification sequences containing isoC and isoG to control NSH, 100 fmol of 12 CEs [to hepatitis G virus (HGV) RNA] were bound individually to microwells and incubated with natural sequence amplifier and alkaline phosphatase probe or system 8 (isoC and isoG) amplifier and alkaline phosphatase probe. Binding was measured by dioxetane chemiluminescence (25,26) RLU. The results are shown in Table 3 .
The RLU of the no CE control, which represents assay NSB (non-specific binding), was subtracted from the RLU of individual CE probes to highlight sequence-specific binding. The NSB of the natural sequence amplifier and alkaline phosphatase probe was 10.9 RLU and the NSB of the isoC, isoG amplifier and alkaline phosphatase probe was 3.0 RLU. NSH Background < 5 RLU is not significant in view of the natural sequence NSB value. The natural sequence amplifier showed sequence-specific background with seven of the 12 oligonucleotide probes, ranging from 1200 to 12 RLU. The 1200 RLU background of probe HGV.225 is the highest ever observed. Computer modeling of the background with this probe suggests that the amplifier repeat sequence forms two 5mer hybrids with the CE separated by a 5 nt bulge. The background is most likely caused by the binding of multiple amplifier repeat sequences to multiple CE probes on the well surface (polyvalent binding). The indicated CE probe (100 fmol) was bound to microwells and incubated with either natural sequence amplifier and alkaline phosphatase probe or the isoC,isoG amplifier and isoC,isoG alkaline phosphatase probe. Hybrids were quantified by dioxetane chemiluminescence in RLU. The value of the no CE probe control, which represents NSB was subtracted from the total noise to yield the NSH of each CE probe. Oligonucleotide targets (5 attomol), listed in Table 2 , complementary to either the alkaline phosphatase probe, the amplifier or the preamplifier were hybridized to the CP on microtiter wells. The oligonucleotide targets were detected with the indicated amplification molecules and the hybridization signal measured by dioxetane chemiluminescence in RLU. Noise = RLU associated with no oligonucleotide target.
The system 8 amplifier and alkaline phosphatase probe showed no background (<2 RLU) with any of the 12 CE probes. The absence of NSH to system 8 amplifier and alkaline phosphatase probe was also observed for 30 CE probes designed to five different cytokine mRNAs; the natural amplifier again showed sequence-specific variation of background, ranging from 35 to 0 RLU (data not shown).
Sensitivity improves with each additional layer of amplification
Control over NSH with isoC and isoG (system 8 amplification) should in principle allow the use of larger preamplifiers and larger amplifiers or the use of multiple layers of amplification to improve sensitivity since signal can be augmented without equal amplification of noise. To test this concept, 5 attomol of three different isoC, isoG oligonucleotide targets (Table 2) were hybridized to the CP on microtiter wells. Target number 1 was detected by hybridization with the alkaline phosphatase probe; target number 2 was detected by hybridization with the amplifier, followed by the alkaline phosphatase probe; target number 3 was detected by hybridization with the preamplifier, followed by the amplifier, followed by the alkaline phosphatase probe. The sensitivity was determined by dioxetane chemiluminescence. The results are shown in Table 4 .
Detection of 5 attomol of oligonucleotide target with alkaline phosphatase probe had an S/N of 5.5; a two-layered amplification had an S/N of 19.6; a three-layered amplification had an S/N of 154.3. By extension, it is likely that a four layered system will increase the sensitivity of the three-layered system. A 30 site bDNA amplifier improved sensitivity another 1.4-fold (data not shown) as compared to the 15 site bDNA amplifier used in this experiment.
Detection of 60 molecules of HIV RNA with system 8 bDNA assay
To test the performance of system 8 detection of an RNA target, the HIV POL RNA sequence was chosen.
An HIV RNA standard curve was prepared by serial dilution of virus in negative human plasma and was titered against an HIV POL RNA standard quantified by phosphate analysis and confirmed by OD 260 and hyperchromicity (27) . The samples were hybridized overnight in quadruplicate to the oligonucleotide probes in microtiter wells. The captured RNA was detected by dioxetane chemiluminescence following system 8 amplification. The results are shown in Table 5 . In three independent experiments, serial dilutions of HIV (prepared from frozen plasma and quantified against the standard RNA transcript) were incubated overnight in microwells with 20 CE and 54 LE oligonucleotides and the signal was amplified with the system 8 preamplifier, amplifier and alkaline phosphatase probes. Dioxetane chemiluminescence was measured in RLU. Noise = no HIV (negative human plasma). Linearity (dose-response) and Detection limit are defined in Materials and Methods. Signals are the average of four determinations.
The three assays each have ∼5% CV. The linearity and detection limit were calculated as described in Materials and Methods for each target level T.
The average detection limit of the three experiments is 59 ± 23 molecules: the percent CV of the detection limits reflect the dose-response. The better the linearity of S -N versus T, the lower the percent CV of the detection limit. A perfectly linear dose-response = 100% linearity. The curves thus show precise quantification down to the limit of 60 molecules/ml.
Utility of system 8 bDNA assay in monitoring HIV-infected patients on triple drug therapy
The system 8 bDNA assay was used to measure viral load in 87 samples from HIV-infected patients on various therapy regimens, including triple drug therapy consisting of Nelfinavir, AZT and 3TC. Figure 2 summarizes the results of this study.
The viral load of the 11 patients showed a nearly monotonic decline to below the assay detection limit during the treatment. A Figure 2 . Quantification of HIV RNA/ml in 11 patients over time. Plasma was collected from the patients at the indicated time intervals and stored at -80_C in David Ho's laboratory. Duplicate 1 ml samples were concentrated by centrifugation and system 8 bDNA assays were run at Chiron. Serial dilutions of virus (quantified against standard HIV POL RNA) were used as a standard curve, which was run in quadruplicate. Each point shown on the graph is a single determination.
total of 47 samples (54%) quantified above the detection limit and 78 samples (90%) quantified above zero. Only the development of a still more sensitive assay will be able to validate the positivity of the 31 samples quantifying between 0 and the detection limit. In spite of the fact that the average sample contained ∼130 virions/ml, the average CV (of the RLU) of the duplicate samples was only 14%.
The HIV 2.0 bDNA assay was previously performed on these samples, all of which were below the detection limit of 500 molecules/ml. This is in good agreement with the current study in which 76 out of 87 samples quantified <500 molecules/ml and 10 out of 11 quantified between 500 and 1000 molecules/ml.
DISCUSSION
A more sensitive branched DNA assay has been developed to quantify nucleic acid targets <100 molecules/ml. This system 8 bDNA assay employs isoC and isoG nucleotides in the amplification molecules to reduce backgrounds and allow for stronger amplification. System 8 amplification was used to show that triple therapy is at least eight times more effective (<60 molecules/ml) than determined using the previous version of the branched DNA assay (<500 molecules/ml). If 10 ml samples were concentrated before the assay, the assay could theoretically detect ∼6 HIV RNA/ml or 3 virions/ml.
In theory the system 8 bDNA assay can be made considerably more sensitive not only by increasing volume, but also by increasing the S/N ratio. Most of the background is coming from LE NSB and amplifier NSB (data not shown). By using cruciform LEs, a design in which two LE probes must bind the target in the correct orientation to bridge the preamplifier, most of the LE NSB can in theory be removed (18) . By finding more effective blockers for the solid phase or by redesigning the branched DNA molecule or the solid phase itself, much of the amplifier's NSB can be removed. Alternatively, by using sequences of reduced complexity (such as trinucleotide repeats), lower concentrations of the amplification molecules can be used during hybridization, resulting in reduced NSB. Additional layers of amplification can also be added.
A prototype system 8 bDNA assay has also been developed to quantify HCV RNA in plasma. A total of 12 2′-O-methyl probes (eight LE and four CE) were designed to the well-conserved 5′ untranslated region of the genome. The assay has a detection limit of 200 molecules (unpublished data), which is ∼50-fold better than the HCV 2.0 Quantiplex TM assay (15) .
The system 8 bDNA assay should also be useful in other hybridization assays. In both filter and in situ hybridization assays, for example, billions of overlapping, unique oligonucleotide sequences are available for possible NSH to probes. The ability to amplify the signal without amplifying noise from hybridization of amplification molecules to sample nucleic acid sequences should greatly improve the sensitivity of these assays. Currently, in situ PCR is the standard for detection of single copy DNA sequences in cells (28, 29) ; in situ RT-PCR has occasionally been problematic for mRNA detection (30) (31) (32) (33) . RNA targets that are partially degraded or intramolecularly crosslinked at selected sites should pose no special problems for in situ bDNA assays since priming and reverse transcription are not required. As in assays that target DNA, multiple oligonucleotides will be used to label target RNA in cells; failure to bind one or more of these oligonucleotides is of no real consequence. Quantification may also be possible with the in situ bDNA assay with proper selection of internal standards. The sensitivity of the system 8 bDNA filter and in situ hybridization assays should be limited mostly by the specificity of the oligonucleotide probes. Empirical selection of the best LE oligonucleotide probes and the use of the cruciform design (18) should prove most useful in optimizing specificity.
The isoC-isoG base pair may find utility in several other areas. Amplification of weak signals from immunoassays, particularly with low titer antigens on the surface of cells or within cells, should be possible. In multiplex bDNA hybridization analysis, many targets will be analyzed simultaneously using many CPs and CE sequences. The ability to control NSH of the labeling system with any of the multiple capturing systems will be critical to the success. Combinatorial fluorescence (34) can be used in multiplex applications to increase the specificity and the reliability of target detection at very low levels. With a six base code containing isoC and isoG nucleotides, it is relatively easy to construct four complete labeling systems (preamplifier, amplifier, labeled probe) that will have no cross-hybridization greater than a 3mer with each other.
In nanotechnology, DNA is a more useful framework than other biopolymers because of the regularity and the predictability of the structures that form when unique sequences are mixed together under appropriate hybridization conditions (35, 36) . The use of isoC-isoG in these constructions should allow more intricate structures to be formed with greater control over the specificity of the hybridizations.
Provided that isoC and isoG are not toxic, they may find utility in oligonucleotide therapeutics. The isoC-isoG base pair could be used to replace selected C-G base pairs to increase the specificity of nucleic acid aptamers (37) (38) (39) and decoys (40) . This should reduce undesirable NSH of the aptamers or decoys to cellular nucleic acid sequences. The use of isoC and isoG in constructing nanomachines for delivery of therapeutics to target cells can also be envisioned.
Other base pairs that may be useful in these applications have been defined, including the κ-π base pair with three hydrogen bonds (22, 23) and a stability similar to the A-T base pair (41, 42) . With an eight base code, sequences of even greater uniqueness and specificity can be devised for all of the above applications.
Eventually, quantification with all DNA probe assays (including quantitative PCR) will be limited by Poisson sampling error. To analyze this, the assay can be conveniently divided into three steps, each of which has an associated probability distribution and variance (σ 2 ): (i) pipetting the sample containing n target molecules (Poisson distribution, σP 2 = n); (ii) capture of the targets (binomial distribution, σb 2 = nPq), where P = probability of capture and q = 1 -P; and (iii) amplification and detection [a normal distribution, σad 2 = (CV ad × n) 2 ], where CV ad = the CV of the amplification and detection steps. By summing the variances and rearranging, the total assay CV may be written as:
The following conclusions can be drawn from this formula. The contribution to the total assay CV from the different steps in the assay depends on the target level. Capture efficiency makes very little difference above five molecules. Below 25 molecules the Poisson contribution dominates the total CV. The accuracy of quantification of target levels between 50 and 500 molecules is significantly affected by the CV of the amplification/detection reaction. With a CV ad of 5%, 100 molecules are detected with a CV of 11-12%; with a CV ad of 30%, the assay CV is 32%.
With 25 molecules in a sample, a 20% CV of quantification is expected in the first pipetting step of the assay. With an amplification/detection CV of 5% the minimum assay CV of quantification would be between 21% (99% efficient capture) and 23% (30% efficient capture). At five molecules, the overall CV will be at least 45%. Thus as the assay detection limit approaches one molecule, it will cease to quantify target precisely well before detectable signals disappear. One solution is to fragment the target in a volume much larger than the assay volume. In this way one target becomes many mini-targets prior to sampling. Target fragmentation should also improve the hybridization efficiency of the probes to the target (due to reduced secondary and tertiary structure) and the capture of the target (due to less steric hindrance).
